Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
作者机构：School of Life SciencesChongqing UniversityChongqing 400044China Head and Neck Cancer CenterChongqing University Cancer HospitalChongqing 400000China
出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)
年 卷 期：2024年第15卷第8期
页 面：1002-1020页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by The Fundamental Research Funds for the Central Universities,No.2019CDYGYB024 The National Natural Science Foundation of China,No.31300726 The Chongqing Primary and Middle School Innovation Talent Training Project,No.CY220113
主 题：Immunotherapy Immune checkpoint inhibitors Immune-related adverse events Biomarkers Cancers
摘 要：Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer ***,their widespread clinical application has led to a notable surge in immune-related adverse events(irAEs),significantly affecting the efficacy and survival rates of patients undergoing ICI *** conventional hematological and imaging tests are adept at detecting organ-specific toxicities,distinguishing adverse reactions from those induced by viruses,bacteria,or immune diseases remains a formidable ***,there exists an urgent imperative for reliable biomarkers capable of accurately predicting or diagnosing ***,a thorough review of existing studies on irAEs biomarkers is *** review commences by providing a succinct over-view of major irAEs,followed by a comprehensive summary of irAEs biomarkers across various ***,we delve into innovative methodologies such as machine learning,single-cell RNA sequencing,multiomics analysis,and gut microbiota profiling to identify novel,robust biomarkers that can facilitate precise irAEs diagnosis or ***,this review furnishes a concise exposition of irAEs mechanisms to augment understanding of irAEs prediction,diagnosis,and treatment strategies.
维普期刊数据库